• PDF / 169,947 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 100 Downloads / 127 Views

DOWNLOAD

REPORT

---

1

Chlorpromazine/promazine/ zuclopenthixol Dizziness, sedation and hypotension: 5 case reports In a study involving 77 patients who had been treated with first generation antipsychotics (FGA) for psychomotor agitation at a psychiatry inpatient clinic in Siena, Italy, 5 patients [ages and sexes not stated] were described, who developed dizziness (1 patient), sedation (2 patients) or hypotension (2 patients) during treatment with chlorpromazine, promazine or zuclopenthixol. All the patients, who had been diagnosed with psychomotor agitation, started receiving FGA therapy comprising chlorpromazine (n=2), promazine (n=1) or zuclopenthixol (n=2) [dosages and routes not stated]. Subsequently, all the patients developed side-effects of the drugs, which were manifested as dizziness in one patient and mild hypotension in another patient (both these patients had been receiving zuclopenthixol [zuclopentixol]), another patient developed sedation (who had been receiving promazine), another patient developed moderate sedation, and the remaining patient developed cardiovascular side effect manifesting as mild hypotension (both these patients had been receiving chlorpromazine) [durations of treatments to reactions onsets and outcomes not stated]. Author comment: "Only 11,7% of subjects developed mild to moderate side effects following FGA administration: 1 subject treated with zuclopentixol developed dizziness and one mild hypotension, 1 subject on promazine. . .developed sedation. Of the patients treated with chlorpromazine. . .sedation (moderate in 1 patient) while only 1 subject showed cardiovascular side effects (mild hypotension)." Scala L, et al. P.618 First generation antipsychotics in the treatment of psychomotor agitation: Efficacy and tolerability. European Neuropsychopharmacology 29 (Suppl. 6): S424 abstr. P.618, Dec 2019. Available from: URL: http://doi.org/10.1016/j.euroneuro.2019.09.602 [abstract] 803443966 Italy

0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 4 Jan 2020 No. 1785